Inhibition of superoxide generation and myeloperoxidase release by carvedilol after receptor and nonreceptor stimulation of human neutrophils

Neuroendocrinology Letters

Volumn 29, Issue 5, 2008, Pages 790-793

  Mačičková, Tatiana ^a   Pečivová, Jana ^a   Nosál, Radomír ^a   Lojek, Antonín ^b   Pekarová, Michaela ^b   Cupaníková, Daniela ^c  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c National Transfusion Service   (Slovakia)

Author keywords

Carvedilol; Isolated human neutrophils; Myeloperoxidase; Receptor and nonreceptor stimulation; Superoxide generation

Indexed keywords

CALCIMYCIN; CARVEDILOL; CYTOCHROME C; MYELOPEROXIDASE; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SUPEROXIDE; WORTMANNIN;

ARTICLE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL; OXIDATION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETER;

EID: 57149141659     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Åsbrink S, Zickert A, Bratt J, Gyllenhammer H, Palmblad J (2000). No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharmacol. 59: 1007-1013.
2. Babior BM (2000). Phagocytes and oxidative stress. Am J Med. 109: 33-44.
3. Brennann ML, Hazen SL (2003). Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol. 4: 353-359.
4. Butler S, Wang R, Wunder SL, Cheng HY, Randall CS (2006). Perturbing effects of carvedilol on a model membrane system: Role of lipophilicity and chemical structure. Biophys Chem. 119: 307-315.
5. Carreira RS, Monteiro P, Gonçalves LM, Providência LA (2006). Carvedilol: Just another beta-blocker or a powerful cardioprotector? Cardiovacs Hematol Dis Drug Targets. 6: 257-266.
6. Dandona P, Karne R, Ghanim M, Hamouda W, Aljada A, Magsino G Jr (2000). Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 101: 122-124.
7. 1-antagonist dithiaden in human PMN leukocytes. Free Rad Res. 36: 975-980.
8. Drábiková K, Jančinová V, Nosál' R, Solík P, Murín J, Holomáňová D (2006). On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo. Neuroendocrinol Lett. 27: 138-140.
9. Hare JM (2004). Nitroso-redox balance in the cardiovascular system. N Engl J Med. 351: 2112-2114.
10. Karlson A, Dahlgren C (2002). Assembly and activation of the neutrophil NADPH oxiclase in granule membranes. Antioxid Redox Signal. 4: 49-60.
11. 2+ influx channels in leukocytes. A therapeutic target? Trends Pharmacol Sci. 23: 63-70.
12. Maes M, Mihaylova I, Kubera M, Bosmans E (2007). Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuroendocrinol Lett. 28: 463-469.
13. Moravcová A, Lojek A, Číž M, Pečivová J, Jančinová V, Nosál' R (2007). The effect of carvedilol on the oxidative burst of rat phagocytes. Chem Listy. 101: 232-233.
14. Nosál' R, Jančinová V, Číž M, Drábiková k, Lojek A, Fábryová V (2005). Inhibition of chemiluminescence by carvedilol in the cell-free system, whole human blood and blood cells. Scand J Clin Lab Invest. 65: 55-64.
15. Pečivová J, Mačičková T, Lojek A, Gallová L, Číž M., Nosál' R, et al (2006). Effect of carvedilol on reactive oxygen species and enzymes linking innate and adaptive immunity. Neuroendocrinol Lett. 27: 160-163.
16. Pečivová J, Mačičková T, Lojek A, Gallová L, Číž M, Nosál' R, et al (2007). In vitro effect of carvedilol on professional phagocytes. Pharmacology. 79: 86-92.
17. Petríková M, Jančinová V, Nosál' R, Májeková L, Danihelová E (2002). Antiplatelet activity of carvedilol in comparison to propranolol. Platelets. 13: 479-485.
18. Yue TL, McKenna PJ, Ruffolo RR Jr, Feuerstein G (1992). Carvedilol, a new beta - adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol. 214: 277-280.